RxDoctor Payments Data

Rebecca Woodbury

Family · Hickory, NCNPI 1780225599

Payments from drug & device makers

$7,688in general payments, 2019–2025

Across 432 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$908
  • AstraZeneca$605
  • Lilly USA, LLC$523
  • Preventric Diagnostics, Inc.$469
  • Bayer$295
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$7,688100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,688 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$29,782
Medicare patients
90
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide18$18,810
JardianceEmpagliflozin12$9,584
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,940
Gentamicin Sulfate24$879
Gabapentin66$571
Atorvastatin Calcium40$450
Levothyroxine Sodium60$344
SsdSilver Sulfadiazine40$316
Losartan Potassium44$298
Lisinopril55$295
Albuterol Sulfate HfaAlbuterol Sulfate17$254
Omeprazole32$224
Sertraline Hcl35$218
Amlodipine Besylate45$212
Duloxetine Hcl12$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$523$18,81018 claims
Boehringer IngelheimJardiance$286$9,58412 claims
AstraZenecaBreztri Aerosphere$605$6,94011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$84$34460 claims
Almatica Pharma LLCSertraline Hcl$31$21835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →